What’s Acceptable Profitability For KT Corporation (KT) and Corcept Therapeutics Incorporated (CORT)?

You should consider shares of KT Corporation (NYSE:KT) and Corcept Therapeutics Incorporated (NASDAQ:CORT) if you are looking for a great stocks to invest in. Starting with the KT shares, which traded at $11.25 at the close of the recent session, dropping -1.92%. On Friday, the company’s shares shed -$0.22 from its value which represented in intraday trading. The stock is now -24.60% lower in year-to-date (YTD) trading. KT’s intraday high was $11.45 while its lowest price touched $11.20. The stock’s 52-week high price is $15.42, which means the current price is at -27.06%. In terms of trading activity, the daily trading volume fell to 636668 against 200-day average trading volume of 784,938 shares.

What are analyst forecasts for KT Corporation (NYSE:KT)?

At a consensus rating of 3.50, KT is trending as a streaking Moderate Buy, as it has been the case a month ago when 4 analysts called it a Moderate Buy. Two months ago, 2 analysts recommended, on average, that KT stock is a Hold. The Technology company’s shares’ overall bearish trend saw it close higher on Friday compared to its opening price of $11.36 on the day.

Forecasts for KT Corporation (NYSE:KT) give the stock a fair value for the growth of 24.19% from its last price. The 12-month price forecast for the stock by analysts puts the stock’s mean price target at $14.84, which means the price per share could rise by nearly $3.59. The price range target is between a low of $10.73 and a high of $17.01. The stock would need to gain by about $33.86 to hit the estimated high or 0.97% from its 12-month low.

The consensus among 25 analysts is that it is a good time for one to Overweight in the KT Corporation. 14 analysts rate KT as a Buy, with 1 of 25 analysts rate it as a Sell. 6 have valued the stock as Overweight and 4 have recommended that investors Hold.

KT Corporation (NYSE:KT) Upgrades and Downgrades

In terms of rating changes, Macquarie on October 07, 2019, Downgrade KT Corporation (KT) at Neutral. Analysts at Nomura have assigned a Neutral rating for the stock in their research note on December 07, 2018. Moreover, Nomura analysts issued a rating of Reduce for the stock on April 16, 2018. On February 06, 2018, the stock earned a Neutral rating due to an analyst call from Nomura, while analysts from Credit Suisse on February 06, 2018 suggested that the stock is Neutral.

Corcept Therapeutics Incorporated (NASDAQ:CORT) adds -$0.38 on Friday

The CORT stock has tanked -3.97% year-to-date and is currently trading at $12.83, which is -34.14% below its 52-week high. The company shares lost -2.88% on the day and have risen nearly 40.37% off a low hit. At current levels, Corcept Therapeutics Incorporated has a valuation of about $285.40M. As of 11/29/19, this stock has fallen -1.08% during the week and closed at $13.21 in the previous session. However, recent Corcept Therapeutics Incorporated stock performance shows that CORT shares are -10.90% down over the last month, and 1.74% up for the last three months.

Earnings per share (EPS) estimates for the current quarter are $0.15, with the trailing 12-month share earnings at $0.71. The ratio is expected to be up by 28.30% for the current year 2019 and 27.30% for next year. Over the next 5-year period, earnings per share will be -41.40%. But will the CORT stock surprise in the current quarter results, where the $0.22 actual EPS reported on 9/29/2019 surprised by 10.00% or was higher by $0.02 from the estimated $0.2.

Sales Growth to climb 13.70% for the year

How well will Corcept Therapeutics Incorporated perform as a business over the current quarter, year and next 5-year period? Compared to the year-ago quarter, analysts forecast the company to bring in between $82.2M and $91.47M in current quarter sales. The consensus estimated for the current quarter is $87.85M from sales. Forecasts for this fiscal year are between $300.8M and $310.06M and the consensus estimate for sales is at $306.44M.

Who owns shares in Corcept Therapeutics Incorporated (CORT)?

Let’s briefly focus on the share ownership of the Corcept Therapeutics Incorporated (NASDAQ:CORT) stock, where we find that 79.82% of shares are held by institutions. Blackrock Inc. tops the list of institutional owners as it is holding 15.54 million shares or 13.60% of shares outstanding. Vanguard Group, Inc. (The) and Federated Investors, Inc. held 10.91 million and 9.24 million representing 9.54% and 8.09% respectively at the close of the last trading session. As of Sep 29, 2019, Ingalls & Snyder accounted for 8.71 million shares at over 123.15 million. This represented 7.62% of shares outstanding. Renaissance Technologies, LLC held 6.52 million shares at over 92.22 million representing 5.71% of shares outstanding.

CORT Insider Activity

Insider activity can also give a signal in terms of price direction. Looking at Corcept Therapeutics Incorporated (CORT), a total of 30000 shares have been sold by insiders over the last 6 months while 364218 shares were added in the same time span. On 12/12/2018, Chief Executive Officer by the name Belanoff Joseph K sold 217115.0 shares worth $4.1 million at the price of $19.01 per share. Filings also show that Belanoff Joseph K sold a total of 217115.0 shares on 12/12/2018 valued at $4.1 million. Since the last insider activity, the company’s share price has dropped -24.75%.